Esketamine Hydrochloride Patent Expiration
Esketamine Hydrochloride is Used for treatment-resistant depression in adults. It was first introduced by Janssen Pharmaceuticals Inc
Esketamine Hydrochloride Patents
Given below is the list of patents protecting Esketamine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Spravato | US11883526 | Esketamine for the treatment of depression | Feb 18, 2040 | Janssen Pharms |
| Spravato | US10869844 | Methods for the treatment of depression | Sep 10, 2035 | Janssen Pharms |
| Spravato | US11173134 | Methods for the treatment of depression | Sep 10, 2035 | Janssen Pharms |
| Spravato | US11311500 | Methods for the treatment of depression | Sep 10, 2035 | Janssen Pharms |
| Spravato | US11446260 | Pharmaceutical composition of S-ketamine hydrochloride | Mar 14, 2034 | Janssen Pharms |
| Spravato | US8785500 | Intranasal administration of ketamine to treat depression | Mar 05, 2033 | Janssen Pharms |
| Spravato | US9592207 | Intranasal administration of ketamine to treat depression | Mar 20, 2027 | Janssen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Esketamine Hydrochloride's patents.
Latest Legal Activities on Esketamine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Esketamine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2024 | US10869844 |
| Email Notification Critical
| 30 Jan, 2024 | US11883526 |
| Recordation of Patent Grant Mailed Critical
| 30 Jan, 2024 | US11883526 |
| Patent Issue Date Used in PTA Calculation Critical
| 30 Jan, 2024 | US11883526 |
| Patent eGrant Notification | 30 Jan, 2024 | US11883526 |
| Recordation of Patent eGrant | 30 Jan, 2024 | US11883526 |
| Mail Patent eGrant Notification | 30 Jan, 2024 | US11883526 |
| Email Notification Critical
| 11 Jan, 2024 | US11883526 |
| Issue Notification Mailed Critical
| 10 Jan, 2024 | US11883526 |
| Dispatch to FDC | 20 Dec, 2023 | US11883526 |
Esketamine Hydrochloride's Family Patents
